logo
China to make all hospitals offer epidurals to incentivize childbirth

China to make all hospitals offer epidurals to incentivize childbirth

CNN2 days ago

China said that by the end of this year all tertiary level hospitals must offer epidural anesthesia during childbirth, a move it said would help promote a 'friendly childbearing environment' for women.
Tertiary hospitals – those with more than 500 beds – must provide epidural anesthesia services by 2025 while secondary hospitals – those containing more than 100 beds – must provide the services by 2027, China's National Health Commission (NHC) said in a statement last week.
Authorities are struggling to boost birth rates in the world's second largest economy after China's population fell for a third consecutive year in 2024 with experts warning the downturn will worsen in the coming years.
Around 30% of pregnant women in China receive anesthesia to relieve pain during childbirth, compared with more than 70% in some developed countries, the official China Daily said.
The World Health Organization recommends epidurals for healthy pregnant women requesting pain relief and it is widely utilized in many countries around the world, including France, where around 82% of pregnant women opt to have one, and in the United States and Canada where more than 67% do.
The move will 'improve the comfort level and security of medical services' and 'further enhance people's sense of happiness and promote a friendly childbearing environment,' the NHC said.
A growing number of provinces across China are also beginning to include childbirth anesthesia costs as part of their medical insurance schemes to encourage more women to have children.
High childcare costs as well as job uncertainty and a slowing economy have discouraged many young Chinese from getting married and starting a family.
In June, health authorities in China's southwestern Sichuan province proposed to extend marriage leave up to 25 days and maternity leave up to 150 days, to help create a 'fertility-friendly society.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

DHL to Invest €500 Million on Africa, Middle East Expansion
DHL to Invest €500 Million on Africa, Middle East Expansion

Bloomberg

time2 hours ago

  • Bloomberg

DHL to Invest €500 Million on Africa, Middle East Expansion

Logistics giant DHL Group plans to invest about €500 million ($575 million) in health-care services in Africa and the Middle East over the next five years to capitalize on China's push into the regions. The German company is looking particularly at Africa for growth opportunities, with time-critical shipments of vaccines, stem-cells and cryogenics all target areas, EMEA health-care head Annette Naude said in an interview.

Wheat Ridge to allow freestanding emergency care facility to be built on Wadsworth corridor in the Colorado city
Wheat Ridge to allow freestanding emergency care facility to be built on Wadsworth corridor in the Colorado city

CBS News

time3 hours ago

  • CBS News

Wheat Ridge to allow freestanding emergency care facility to be built on Wadsworth corridor in the Colorado city

At June 9's Wheat Ridge City Council meeting, an ordinance was passed that effectively paved the way for freestanding emergency departments to be built and operate within the city limits. CBS One such area is slated to be on the corner of 38th Street and Wadsworth Boulevard. "(This) for the first time allows freestanding emergency departments to be built in mixed use zones," said Dan Larson, Wheat Ridge's District 4 Councilor. Freestanding emergency departments -- also known as freestanding emergency rooms -- are effectively emergency care facilities not attached to a hospital. If someone is dealing with a life threatening condition, first responders can take them to a facility like this before deciding if they will send them further to a full-service hospital. The condition of giving this lot of land to HCA Healthone, who operate Rose Medical Center in Denver, is that the freestanding ER also be a part of a larger medical campus in the adjacent plaza on 38th. The total size of the lot is about 5 acres. While the ordinance passed in a council meeting on Monday, it wasn't without some resistance from residents and health care professionals. One big issue revolved around individuals' understanding what freestanding ERs actually are. "It cannot and does not provide a level of care to the level of a real hospital and many of your elderly especially at Wheat Ridge," said Douglas Martel, a former cardiologist at Intermountain Lutheran, during public comment. Critiques like his specifically revolved around cardiac emergencies like heart attacks or strokes. Freestanding ERs, he argued, were not capable of handling those types of emergencies the same ways that full service hospitals are and thus might confuse potential patients and lose them precious time to be treated. "If you want to keep excellent care in your community and for your constituents you will oppose this ordinance," Martel advocated. Other issues from residents included billing and insurance coverage as well as accessibility. Freestanding ERs built a reputation in the early 2010s for "being predatory," as Larson put it, to patients with exorbitant costs that they didn't account for until after treatment. Councilman Larson told CBS Colorado that a big reason the freestanding ER was on the table was because of Intermountain Lutheran's move to the west side of town, creating a need for an emergency care center on the east side. Additionally, Larson said, the regulatory standards for these types of clinics had been changed, allowing Wheat Ridge to not worry about having too many of these services in ways others have. "The regulatory environment in the state of Colorado in terms of licensing, in terms of building practices has changed," Larson said. "The city of Wheat Ridge has changed."

Fast Five Quiz: Opioid Use Disorder
Fast Five Quiz: Opioid Use Disorder

Medscape

time4 hours ago

  • Medscape

Fast Five Quiz: Opioid Use Disorder

Opioid use disorder (OUD) currently impacts approximately 16 million people worldwide. It is considered a significant public health issue, with experts noting a 'burden that is increasing' globally. As research into optimal management of OUD evolves, updates to clinical guidelines emphasize a more individualized approach to pharmacologic treatment, psychosocial support, and special considerations for specific patient populations, such as pregnant individuals. However, OUD remains a complex disease that comes with many serious health and legal concerns for both patients and clinicians. What do you know about OUD? Check your knowledge with this quick quiz. Despite pharmacologic treatment being known to be highly effective for treating OUD, a CDC report states that 30% of patients with OUD who require OUD treatment received only nonpharmacologic treatment. Further, 43% of patients did not perceive a need for OUD treatment at all. In this significant report, males aged 35-49 years were most likely to receive OUD treatment with medications, while females and younger and older adults had lower rates of access to pharmacologic interventions. The CDC concluded that engaging patients needing OUD treatment with pharmacologic interventions is 'essential.' Learn more about essential statistics for OUD. Data from a predictive-model study indicate that service setting was the strongest predictor for premature discontinuation of OUD treatment. The strength of this predictor declined with length of stay, becoming negligent after 365 days. Other system-level factors such as geographic region, primary source of payment for treatment, and referral source were also strong predictors of early discontinuation; individual factors such as age of first use, sex, and race were less predictive. Previous research cited by the study has also stressed the importance of reducing system-level barriers to care, and the updated federal guidance for opioid treatment programs have expanded access in several ways. Learn more about OUD guidance. Precipitated withdrawal can occur when transferring a patient from methadone to buprenorphine due to buprenorphine being only a partial opioid agonist; as such, the traditional method of transfer involves putting the patient in a controlled, moderate withdrawal state before initiating buprenorphine therapy. However, a novel dosing strategy called microinduction, which involves starting buprenorphine at submilligram doses (or 'low-dose induction'), and cross-tapering with methadone can prevent precipitated withdrawal. Additionally, this method is ideal for patients who want to switch from methadone to buprenorphine and those with chronic use of intravenous or intranasal fentanyl. A recent systematic review found that microinduction and traditional transfer methods had similar rates of successful induction of buprenorphine at 95.6%. Learn more about safe withdrawal practices for OUD. Both the CDC and the latest American Society of Addiction Medicine (ASAM) guidelines specifically state that pharmacotherapy for OUD should be offered as early as possible in pregnancy to prevent harms to both the patient and the fetus, noting that pharmacotherapy for OUD has been associated with improved maternal outcomes. ASAM specifically states, 'increasing the dose or split dosing is often required, especially in the third trimester.' Federal guidelines emphasize that pregnant individuals seeking treatment for OUD are considered a priority for enrollment in opioid treatment programs. Once receiving treatment, they do not generally recommended medically supervised withdrawal from pharmacotherapy for pregnant patients as it might harm the fetus and patient; further, ASAM guidelines state that patients who undergo medically supervised withdrawal are at an increased risk for 'return to opioid use.' However, if a patient decides to proceed with medically supervised withdrawal, ASAM guidelines suggest physicians provide education and resources regarding associated risks. The CDC also specifically recommends against abruptly discontinuing opioids during pregnancy, citing data and resources from the American College of Obstetricians and Gynecologists and the Substance Abuse and Mental Health Services Administration. Learn more about OUD. Federal guidelines specify that opioid treatment programs must conduct at least eight random drug tests per year on their patients. These tests must use FDA approved products that test for commonly abused substances that might affect patient safety, recovery, or adherence to OUD treatment. ASAM affirms this requirement, noting that many patients might need more frequent testing and that eight tests per year 'should be viewed as a minimum.' Learn more about drug testing in OUD. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store